In a move signaling the growing momentum for using clinical data to transform healthcare, Deloitte has acquired Recombinant Data Corp., a fast-growing provider of data warehousing and clinical intelligence solutions that enable advances in personalised medicine, translational research and healthcare performance management.
Based in Newton, Mass., Recombinant’s ascendency has been driven by opportunities in the health provider, medical research, life sciences and government health markets as they relate to enterprise data integration, population health analytics, clinical genome data assimilation and performance management for accountable care organisations (ACOs).
Recombinant has enjoyed significant year-over-year growth since it was founded in 2005, defying the economic downturn by emphasising innovation in helping the healthcare industry anticipate a shifting landscape. Recombinant’s business will reside within Deloitte Consulting Innovation under the name “Recombinant By Deloitte.”
“Joining forces with Recombinant represents a bold move around innovation that will open new horizons for Deloitte in the life sciences and healthcare sectors,” said Andrew Vaz, principal and chief innovation officer, Deloitte Consulting LLP. “It will extend the Deloitte brand into hybrid business models in which world-class services are combined with advanced intellectual property assets.”
According to Peter Emerson, chief executive officer of Recombinant, the combination with Deloitte “multiplies in one event our ability to serve clients while opening new opportunities to deliver our products and services more broadly across the marketplace.” Emerson added, “This will allow us to make a greater impact on clients and the direction of healthcare; Deloitte and Recombinant share the same vision on how the industry is changing, and our combination provides a level of scale that can help reshape the clinical informatics industry.”
Recombinant’s services and products help enable the data management that underpin the formation of value-based payment models that link different health players around patient care. Recombinant also helps academic medical centres, federal agencies and life sciences companies conduct translational research and analyse phenomic, genomic and bio banking data in pursing personalised and evidence-based medicine. These solutions can help clients unlock the underlying power of digital data.
“This addition puts Deloitte in a stronger position to help health organisations solve their most complex problems as they adjust to new approaches to care delivery,” said Vaz, who noted that pressure continues to mount for fundamental changes in healthcare.
For more information, please visit: www.deloitte.com